Clinical Outcome for Patients Managed with Low-Dose Cisplatin and Doxorubicin Delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
17
05
2021
accepted:
04
08
2021
pubmed:
7
10
2021
medline:
22
12
2021
entrez:
6
10
2021
Statut:
ppublish
Résumé
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is increasingly used to manage gastric cancer peritoneal metastasis (GCPM). This study analyzed a prospective database of GCPM patients treated with cisplatin and doxorubicin PIPAC (PIPAC-C/D). The outcome criteria were adverse events, pathologic response [peritoneal regression grading score (PRGS)], and overall survival (OS). The PIPAC-C/D procedure was scheduled for 144 patients with a median age of 57 years (range 22-88 years). Access to the abdominal cavity for the first PIPAC failed in 11 patients (7.7 %). A total of 296 procedures were performed for 131 patients. Of the 144 patients, 52 (36.1%) underwent one PIPAC, 32 (22.2%) underwent two PIPACs, 24 (16.7%) underwent three PIPACs, and 21 (14.6%) underwent four or more PIPACs. The overall morbidity/mortality was grade 1 for 22 patients (15.3%), grade 2 for 32 patients (22.2%), grade 3 for 7 patients (4.9%), grade 4 for no patients (0%), and grade 5 for 2 patients (1.4%). Of the 37 patients who had three or more PIPACs eligible for histopathologic response analysis, 27 (73%) had major or complete regression (PRGS 1/2). A median OS of 11 months (range 0-61 months) for the total study population and 16 months (range 2-61 months) for the patients with three or more PIPACs was observed. For 10 patients (7%) who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, the median OS was 15 months (minimum, 4 months; maximum, 27 months). Multivariate analysis showed three or more PIPACs to be an independent prognostic factor for improved OS (hazard ratio, 0.36; p < 0.0001). Repetitive PIPAC-C/D ± systemic chemotherapy is associated with low morbidity and mortality rates. Prospective randomized trials are needed to confirm whether three or more PIPAC-C/Ds improve clinical outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is increasingly used to manage gastric cancer peritoneal metastasis (GCPM).
METHODS
METHODS
This study analyzed a prospective database of GCPM patients treated with cisplatin and doxorubicin PIPAC (PIPAC-C/D). The outcome criteria were adverse events, pathologic response [peritoneal regression grading score (PRGS)], and overall survival (OS).
RESULTS
RESULTS
The PIPAC-C/D procedure was scheduled for 144 patients with a median age of 57 years (range 22-88 years). Access to the abdominal cavity for the first PIPAC failed in 11 patients (7.7 %). A total of 296 procedures were performed for 131 patients. Of the 144 patients, 52 (36.1%) underwent one PIPAC, 32 (22.2%) underwent two PIPACs, 24 (16.7%) underwent three PIPACs, and 21 (14.6%) underwent four or more PIPACs. The overall morbidity/mortality was grade 1 for 22 patients (15.3%), grade 2 for 32 patients (22.2%), grade 3 for 7 patients (4.9%), grade 4 for no patients (0%), and grade 5 for 2 patients (1.4%). Of the 37 patients who had three or more PIPACs eligible for histopathologic response analysis, 27 (73%) had major or complete regression (PRGS 1/2). A median OS of 11 months (range 0-61 months) for the total study population and 16 months (range 2-61 months) for the patients with three or more PIPACs was observed. For 10 patients (7%) who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, the median OS was 15 months (minimum, 4 months; maximum, 27 months). Multivariate analysis showed three or more PIPACs to be an independent prognostic factor for improved OS (hazard ratio, 0.36; p < 0.0001).
CONCLUSIONS
CONCLUSIONS
Repetitive PIPAC-C/D ± systemic chemotherapy is associated with low morbidity and mortality rates. Prospective randomized trials are needed to confirm whether three or more PIPAC-C/Ds improve clinical outcome.
Identifiants
pubmed: 34611790
doi: 10.1245/s10434-021-10860-y
pii: 10.1245/s10434-021-10860-y
doi:
Substances chimiques
Aerosols
0
Doxorubicin
80168379AG
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112-123Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Bray F, Ferlay J, Soerjomatran I, Siegel RL, Torre LA, Semal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
doi: 10.3322/caac.21492
Yarema R, Ohorchak M, Hyrya P, Kovalchuk Y, Safiyan V, Karelin I, et al. Gastric cancer with peritoneal metastases: efficiency of standard treatment methods. WJGO. 2020;12:569–81.
doi: 10.4251/wjgo.v12.i5.569
Peritoneum Registry of the German Society for General and Visceral Surgery (DGAV), for the Peritoneum Surface Oncology Group and members of the StuDoQ, Rau B, Brandl A, Piso P, Pelz J, Busch P, et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23:11–22.
Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.
doi: 10.1016/S0140-6736(18)32557-1
Al-Batran S-E, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3:1237.
doi: 10.1001/jamaoncol.2017.0515
Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53–63.
doi: 10.1007/978-1-4613-1247-5_4
Li F, Tiede B, Massagu J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007;17:3–14.
doi: 10.1038/sj.cr.7310118
Taniguchi K, Yonemura Y, Ishibashi H, Mizumoto A, Wakama S, Cocolini F. Recent advances in the treatment of peritoneal metastasis from gastric cancer. Cancer Rep Rev. 2018;2(2):1–6. https://doi.org/10.15761/CRR.1000148 .
doi: 10.15761/CRR.1000148
Zhang S, Feng R, Pan Z, Lin M, Jiang T, Huang X, et al. Clinical efficacy of combination intravenous and intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis. Curr Pharm Biotechnol. 2018;19(12):956–62. https://doi.org/10.2174/1389201019666181114121145 .
doi: 10.2174/1389201019666181114121145
pubmed: 30426896
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81.
doi: 10.1245/s10434-011-1631-5
Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol. 2014;21:539–46. https://doi.org/10.1245/s10434-013-3208-y .
doi: 10.1245/s10434-013-3208-y
pubmed: 23975319
Kono K, Yong WP, Okayama H, Shabbir A, Momma T, Ohki S, et al. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. Gastric Cancer. 2017;20(Suppl 1):122–7. https://doi.org/10.1007/s10120-016-0660-y .
doi: 10.1007/s10120-016-0660-y
pubmed: 27766496
Badgwell B, Blum M, Das P, Estrella J, Wang K, Ho L, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24:3338–44.
doi: 10.1245/s10434-017-6047-4
Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:19.
doi: 10.1200/JCO.2018.77.8613
Chicago Consensus Working Group, Izquierdo FJ, Schuitevoerder D, et al. The Chicago Consensus on Peritoneal Surface Malignancies: management of gastric metastases. Ann Surg Oncol. 2020;27:1768–73. https://doi.org/10.1245/s10434-020-08320-0 .
Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich FJ, Königsrainer A, et al. Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC). Cancers. 2020;12:34. https://doi.org/10.3390/cancers12010034 .
doi: 10.3390/cancers12010034
Giger-Pabst U, Bucur P, Roger S, Falkenstein TA, Tabchouri N, Le Pape A, et al. Comparison of tissue and blood concentrations of oxaliplatin administrated by different modalities of intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26:4445–51. https://doi.org/10.1245/s10434-019-07695-z .
doi: 10.1245/s10434-019-07695-z
pubmed: 31399820
Shariati M, Lollo G, Matha K, Descamps B, Vanhove C, van de Sande L, et al. Synergy between intraperitoneal aerosolization (PIPAC) and cancer nanomedicine: cisplatin-loaded polyarginine-hyaluronic acid nanocarriers efficiently eradicate peritoneal metastasis of advanced human ovarian cancer. ACS Appl Mater Interfaces. 2020;12:29024–36. https://doi.org/10.1021/acsami.0c05554 .
doi: 10.1021/acsami.0c05554
pubmed: 32506916
Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond M-A. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20:367–73.
doi: 10.1007/s11605-015-2995-9
Giger-Pabst U, Tempfer CB. How to perform safe and technically optimized pressurized intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200 procedures. J Gastrointest Surg. 2018;22:2187–93.
doi: 10.1007/s11605-018-3916-5
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19–23.
doi: 10.1007/s003840050072
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) (PIPACRegis). ClinicalTrials.gov Identifier: NCT03210298. Retrieved at 15 May 2020. https://clinicaltrials.gov/ct2/show/NCT03210298 .
Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura Peritoneum. 2016;1:99–107.
doi: 10.1515/pp-2016-0011
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published 28 May 2009 (v4.03: 14 June 2010). U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute.
Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47:123–7. https://doi.org/10.1016/j.ejso.2020.05.021 .
doi: 10.1016/j.ejso.2020.05.021
pubmed: 32561204
Di Giorgio A, Schena CA, El Halabieh MA, Abatini C, Vita E, Strippoli A, et al. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): a bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol. 2020;34:270–5. https://doi.org/10.1016/j.suronc.2020.05.006 .
doi: 10.1016/j.suronc.2020.05.006
pubmed: 32891341
Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:2178–83.
doi: 10.1016/j.ejso.2017.09.010
Tabchouri N, Buggisch J, Demtröder CR, Thiery J, Rezniczek G, Tempfer CB, et al. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases. Ann Surg Oncol. 2021;28(9):5275–86. https://doi.org/10.1245/s10434-020-09508-0 .
doi: 10.1245/s10434-020-09508-0
pubmed: 33471267
Struller F, Horvath P, Solass W, Weinreich FJ, Strumberg D, Kokkalis MK, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402. https://doi.org/10.1177/1758835919846402 .
doi: 10.1177/1758835919846402
pubmed: 31205501
pmcid: 6535725
Ploug M, Graversen M, Pfeiffer P, Mortensen MB. Bidirectional treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer. 2020;20(1):105. https://doi.org/10.1186/s12885-020-6572-6 .
doi: 10.1186/s12885-020-6572-6
pubmed: 32041558
pmcid: 7011374
Bonnot PE, Rabel T, Lintis A, Laplace N, Bakrin N, Kepenekian V, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated to systemic chemotherapy for gastric cancer with diffuse peritoneal metastases in a palliative setting. J Clin Oncol. 2020;38(15 Suppl):e16538–e16538.
doi: 10.1200/JCO.2020.38.15_suppl.e16538
Gockel I, Jansen-Winkeln B, Haase L, Rhode P, Mehdorn M, Niebisch S, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study. J Gastric Cancer. 2018;18:379–91. https://doi.org/10.5230/jgc.2018.18.e37 .
doi: 10.5230/jgc.2018.18.e37
pubmed: 30607301
pmcid: 6310762
Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology. 2010;78:40–6. https://doi.org/10.1159/000290955 .
doi: 10.1159/000290955
pubmed: 20197706
Nakajima TE, Nakamura K, Takashima A, Kato K, Hamaguchi T, Yamada Y, et al. Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study. Int J Clin Oncol. 2011;16:57–62. https://doi.org/10.1007/s10147-010-0135-9 .
doi: 10.1007/s10147-010-0135-9
pubmed: 20949367
Imamoto H, Oba K, Sakamoto J, Iishi H, Narahara H, Yumiba T, et al. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer. 2011;14:81–90. https://doi.org/10.1007/s10120-011-0016-6 .
doi: 10.1007/s10120-011-0016-6
pubmed: 21327925
Zheng LN, Wen F, Xu P, Zhang S. Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: a systemic review and meta-analysis. World J Clin Cases. 2019;7:3247–58. https://doi.org/10.12998/wjcc.v7.i20.3247 .
doi: 10.12998/wjcc.v7.i20.3247
pubmed: 31667175
pmcid: 6819285
Coccolini F, Ansaloni L, Manfredi R, Campanati L, Poiasina E, Bertoli P, et al. Peritoneal adhesion index (PAI): proposal of a score for the “ignored iceberg” of medicine and surgery. World J Emerg Surg. 2013;8:6.
doi: 10.1186/1749-7922-8-6
Benzerdjeb N, Durieux E, Tantot J, Isaac S, Fontaine J, Harou O, et al. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology. 2020;77:548–59. https://doi.org/10.1111/his.14092 .
doi: 10.1111/his.14092
pubmed: 32060943